The facility will be directed by Nevan Krogan, senior investigator at the Gladstone Institutes, professor of cellular and molecular pharmacology at UCSF and director of the UCSF division of QB3. It will provide scientists from Gladstone, UCSF and QB3 with state-of-the-art mass spectrometry technologies to characterize protein dynamics in complex biological systems. The technologies will enable scientists to acquire unprecedented knowledge about the interactions between genes and the proteins they produce, and help facilitate solutions to unanswered biomedical problems.

‘Thermo Fisher is the perfect partner for this collaboration, both in terms of their technology and their willingness to support and grow the proteomics community,’ stated Krogan. ‘Our research is critically dependent on our ability to perform detailed protein analysis with extreme sensitivity and accuracy. We require the most advanced mass spectrometers to continue our studies.’
The facility will showcase the latest mass spectrometers for detailed biological discovery and quantitation, including the new Orbitrap Fusion Tribrid and TSQ Quantiva Triple Quadrupole LC/MS systems. In addition to enabling innovative research, the Thermo Fisher facility will be a focal point for promoting biological applications of mass spectrometry by hosting an invited lecture series, discussion groups, workshops and trainings.

‘We know that human cells contain approximately 25,000 genes that instruct the synthesis of many thousands of proteins, but we understand the function of only a small subset of these,’ said R. Sanders Williams, president of the Gladstone Institutes. ‘We are deeply grateful to Thermo Fisher for sponsoring this indispensable facility, which will not only illuminate how genes and proteins function but also shed light on the underlying biology of disease for each person.’

‘Gladstone, UCSF, QB3, and Dr. Krogan's lab, including key members such as Jeffrey Johnson, PhD, have been doing exceptional work in the area of genetic and protein mapping in order to gain insight into disease pathways and mutations,’ said Ken Miller, vice president, research product marketing, at Thermo Fisher. ‘Through our collaboration, the new facility will enable researchers to apply state-of-the-art proteomics technologies to this critical area of research. We look forward to building on this collaboration and seeing the promising discoveries to come.’

‘The new Thermo Fisher-sponsored facility will be of great benefit to researchers throughout the UCSF community and beyond,’ said Sam Hawgood, chancellor of UCSF. ‘By using these Thermo Fisher technologies, scientists will succeed in building comprehensive maps of how genes and proteins interact – knowledge that may lead to new drug targets for a host of devastating diseases.’

Additional Links

Our site uses cookies to improve your experience. You can find out more about our use of cookies
in our "standard cookie policy", including
instructions on how to reject and delete cookies if you wish to do so. By continuing to browse this site you agree
to us using cookies as described in our "standard cookie policy".

Our site uses cookies to improve your experience. You can find out more about our use of cookies
in our "standard cookie policy", including
instructions on how to reject and delete cookies if you wish to do so. By continuing to browse this site you agree
to us using cookies as described in our "standard cookie policy".